This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (91)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Infectious Diseases, Other  • Pneumonia  • Alert me on articles by topic  Social Bookmarking   What's this?

James E. Stahl, MD; Michael Barza, MD; Jeffrey DesJardin, MD; Rhonda Martin, RN; Mark H. Eckman, MD

Arch Intern Med. 1999;159:2576-2580.

Background  The choice of antibiotics to treat community-acquired pneumonia (CAP) is primarily empiric, and the effect of this choice on length of stay (LOS) and mortality is largely unknown.

Objective  To examine the impact of antibiotic choice on these outcomes in general medical patients hospitalized with CAP.

Methods  One hundred patients hospitalized with CAP were prospectively identified. Seventy-six met inclusion criteria and were entered into the study. After hospital discharge, each medical chart was examined by 2 independent physicians who verified the admitting diagnosis and entered the data for antimicrobial regimens, a CAP mortality prediction tool, a social and disposition index, and other health outcomes. Patients were stratified according to the antibiotic received. Simple regression techniques were used to examine the correlation between initial therapy, specifically, ceftriaxone sodium or a macrolide, and LOS and mortality.

Results  Patients who received macrolides within the first 24 hours of admission had a markedly shorter LOS (2.8 days) than those not so treated (5.3 days; P=.01). This effect diminished as the interval before administering macrolides increased. Including ceftriaxone as part of the initial therapy did not appear to affect LOS. Patients given a macrolide for initial treatment did not differ significantly from those not treated in terms of mean age, mortality prediction tool score, or Social and Disposition Index score. Eleven of the 12 patients who received macrolides also received a -lactam antibiotic.

Conclusion  Use of macrolides as part of an initial therapeutic regimen appears to be associated with shorter LOS.

From the Divisions of Clinical Decision Making (Drs Stahl and Eckman), Informatics and Telemedicine (Drs Stahl and Eckman), Geographic Medicine and Infectious Diseases (Drs Barza and DesJardin), General Medicine (Drs Stahl and Eckman), and Quality Support Services (Ms Martin), Department of Medicine, New England Medical Center and Tupper Research Institute, Tufts University School of Medicine, Boston, Mass.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTER

Community-Acquired Pneumonia in Elderly Patients and Length of Hospitalization
Luca Masotti, Elena Ceccarelli, Roberto Cappelli, Lucio Barabesi, Sandro Forconi, and Julio A. Ramirez
Arch Intern Med. 2000;160(17):2678-2679.
EXTRACT | FULL TEXT  

RELATED ARTICLES

The Best Treatment for Pneumonia: New Clues, but No Definitive Answers
Scott F. Dowell
Arch Intern Med. 1999;159(21):2511-2512.
EXTRACT | FULL TEXT  

Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With Pneumonia
Patrick P. Gleason, Thomas P. Meehan, Jonathan M. Fine, Deron H. Galusha, and Michael J. Fine
Arch Intern Med. 1999;159(21):2562-2572.
ABSTRACT | FULL TEXT  

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(21):2605-2606.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis
Paul et al.
Eur Respir J 2007;30:525-531.
ABSTRACT | FULL TEXT  

A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia
Arnold et al.
Am. J. Respir. Crit. Care Med. 2007;175:1086-1093.
ABSTRACT | FULL TEXT  

Antibiotics for Bacteremic Pneumonia: Improved Outcomes With Macrolides but Not Fluoroquinolones
Metersky et al.
Chest 2007;131:466-473.
ABSTRACT | FULL TEXT  

Impact of initial antibiotic choice on mortality from pneumococcal pneumonia
Aspa et al.
Eur Respir J 2006;27:1010-1019.
ABSTRACT | FULL TEXT  

A Cost-Minimization Analysis Comparing Azithromycin-Based and Levofloxacin-Based Protocols for the Treatment of Patients Hospitalized With Community-Acquired Pneumonia: Results From the CAP-IN Trial
Samsa et al.
Chest 2005;128:3246-3254.
ABSTRACT | FULL TEXT  

Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors
Schouten et al.
J Antimicrob Chemother 2005;56:575-582.
ABSTRACT | FULL TEXT  

Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
Amsden
J Antimicrob Chemother 2005;55:10-21.
ABSTRACT | FULL TEXT  

Expectorated Sputum for Community-Acquired Pneumonia: A Sacred Cow
Madison and Irwin
Arch Intern Med 2004;164:1725-1727.
FULL TEXT  

Assessment of the Usefulness of Sputum Culture for Diagnosis of Community-Acquired Pneumonia Using the PORT Predictive Scoring System
Garcia-Vazquez et al.
Arch Intern Med 2004;164:1807-1811.
ABSTRACT | FULL TEXT  

Atypical pathogens and respiratory tract infections
Blasi
Eur Respir J 2004;24:171-182.
ABSTRACT | FULL TEXT  

Information Resources Used in Antimicrobial Prescribing
Sellman et al.
J. Am. Med. Inform. Assoc. 2004;11:281-284.
ABSTRACT | FULL TEXT  

Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia
File et al.
Chest 2004;125:1888-1901.
ABSTRACT | FULL TEXT  

Duration of length of stay in pneumonia: influence of clinical factors and hospital type
Menendez et al.
Eur Respir J 2003;22:643-648.
ABSTRACT | FULL TEXT  

Algorithm To Determine Cost Savings of Targeting Antimicrobial Therapy Based on Results of Rapid Diagnostic Testing
Oosterheert et al.
J. Clin. Microbiol. 2003;41:4708-4713.
ABSTRACT | FULL TEXT  

How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review
Oosterheert et al.
J Antimicrob Chemother 2003;52:555-563.
ABSTRACT | FULL TEXT  

Impact of Initial Antibiotic Choice on Clinical Outcomes in Community-Acquired Pneumonia: Analysis of a Hospital Claims-Made Database
Brown et al.
Chest 2003;123:1503-1511.
ABSTRACT | FULL TEXT  

C-reactive protein levels in community-acquired pneumonia
Garcia Vazquez et al.
Eur Respir J 2003;21:702-705.
ABSTRACT | FULL TEXT  

Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers
Chiu et al.
J Antimicrob Chemother 2002;50:1075-1079.
ABSTRACT | FULL TEXT  

Influence of Deviation From Guidelines on the Outcome of Community-Acquired Pneumonia*
Menendez et al.
Chest 2002;122:612-617.
ABSTRACT | FULL TEXT  

Treatment of community-acquired lower respiratory tract infections in adults
Ortqvist
Eur Respir J 2002;20:40S-53s.
ABSTRACT | FULL TEXT  

Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention
Niederman et al.
Am. J. Respir. Crit. Care Med. 2001;163:1730-1754.
FULL TEXT  

Empiric Antibiotic Therapy and Mortality Among Medicare Pneumonia Inpatients in 10 Western States : 1993, 1995, and 1997
Houck et al.
Chest 2001;119:1420-1426.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Gatifloxacin vs Ceftriaxone With a Macrolide for the Treatment of Community-Acquired Pneumonia
Dresser et al.
Chest 2001;119:1439-1448.
ABSTRACT | FULL TEXT  

Community-Acquired Pneumonia in Elderly Patients and Length of Hospitalization
Masotti et al.
Arch Intern Med 2000;160:2678-2679.
FULL TEXT  

Macrolide Treatment for Community-Acquired Pneumonia
JWatch General 1999;1999:3-3.
FULL TEXT  

The Best Treatment for Pneumonia: New Clues, but No Definitive Answers
Dowell
Arch Intern Med 1999;159:2511-2512.
FULL TEXT